学术周报 · IF≥10
眼科领域文献阅读汇编
2026年第39周 (2026-09-23) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
| # | 论文 | 期刊 | IF |
|---|---|---|---|
| 1 | Recent Advances in Alternate Corneal Models for Ophthalmic Safety Testing and Efficacy Studies: A Sp... | Progress in retinal and eye research | IF 16.2 |
| 2 | The Virtual Eye: An Integrative Multiscale Framework for Mechanistic Modelling of Ocular Physiology ... | Progress in retinal and eye research | IF 16.2 |
| 3 | Immunosenescence in Uveitis: From Mechanistic Insights to Therapeutic Implications. | Ageing research reviews | IF 15.5 |
| 4 | Super-enhancer-driven SGK1 activates polyamine metabolism to promote autoimmune uveitis. | Science advances | IF 13.9 |
| 5 | Rosacea in Patients with Skin of Color: Diagnosis and Management. | American journal of clinical dermatology | IF 11.4 |
| 6 | Cataract GWAS meta-analysis and multi-omics Mendelian randomisation inform disease mechanisms and ca... | EBioMedicine | IF 11.2 |
| 7 | Conjunctival Melanocytic Lesions: A Practical Sequential Treatment Approach. | Ophthalmology | IF 10.9 |
| 8 | Centralized Multidisciplinary Retinoblastoma Care Closes the Outcome Gap: Survival and Globe Salvage... | Ophthalmology | IF 10.9 |
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Ophthalmology | 2 | IF 10.9 |
| Progress in retinal and eye research | 2 | IF 16.2 |
| Ageing research reviews | 1 | IF 15.5 |
| EBioMedicine | 1 | IF 11.2 |
| American journal of clinical dermatology | 1 | IF 11.4 |
| Science advances | 1 | IF 13.9 |
1葡萄膜炎与免疫 (2篇)
基础研究 (2篇)
Immunosenescence-the age-associated remodeling of the immune system-has emerged as a potential modifier of chronic inflammatory disease. This review examines the evidence that immunosenescence may contribute to the chronicity, refractoriness, and therapeutic heterogeneity of uveitis, and considers the clinical and translational implications of this framework. It first outlines the features of immune aging, including thymic involution, contraction of the naïve T cell pool, accumulation of memory and terminally differentiated populations, and a chronic low-grade inflammatory state (inflammaging), and discusses signaling pathways that have been associated with these processes, including AMPK-mTOR, NF-κB, cGAS-STING, and JAK-STAT. It then evaluates three complementary but unequal lines of evidence relevant to uveitis: direct human observations from peripheral blood and intraocular fluids, mechanistic support from experimental models, and contextual inference from age-associated ocular disorders. Collectively, these data suggest that age-related immune remodeling may promote breakdown of ocular immune privilege, blood-retinal barrier dysfunction, persistent cytokine signaling, and incomplete response to conventional therapy in selected uveitis phenotypes. Finally, this review discusses therapeutic implications, including Treg enhancement, cytokine-directed approaches, and advanced drug delivery, while emphasizing that direct evidence of immune rejuvenation in human uveitis remains lacking. Ageing does not simply amplify ocular inflammation; it may attenuate selected acute immune responses while impairing resolution and tissue resilience, with effects that depend on disease context. By bridging geroscience and ocular immunology, this review offers a translational framework for understanding refractory intraocular inflammation and highlights future priorities for biomarker development, patient stratification, and precision medicine in uveitis.
中文摘要:免疫衰老——免疫系统与年龄相关的重塑——已成为慢性炎症性疾病的潜在调节因素。本综述审视免疫衰老可能促进葡萄膜炎慢性化、难治性及治疗异质性的证据,并探讨该框架的临床与转化意义。文章首先概述免疫衰老的特征,包括胸腺退化、初始T细胞库收缩、记忆性和终末分化细胞群体积累以及慢性低度炎症状态(炎性衰老),并讨论与这些过程相关的信号通路,包括AMPK-mTOR、NF-κB、cGAS-STING和JAK-STAT。随后,文章评估与葡萄膜炎相关的三条互补但证据强度不等的证据线索:来自外周血和眼内液的人体直接观察、来自实验模型的机制支持,以及来自年龄相关眼部疾病的背景性推断。总体而言,这些数据提示,年龄相关免疫重塑可能在特定葡萄膜炎表型中促进眼免疫豁免破坏、血视网膜屏障功能障碍、持续性细胞因子信号传导以及对常规治疗反应不完全。最后,本综述讨论治疗意义,包括增强调节性T细胞、靶向细胞因子的方法以及先进药物递送,同时强调在人类葡萄膜炎中仍缺乏免疫年轻化的直接证据。衰老并非仅仅放大眼部炎症;它可能减弱某些急性免疫反应,同时损害炎症消退和组织韧性,其效应取决于疾病背景。通过连接老年科学与眼部免疫学,本综述为理解难治性眼内炎症提供了转化框架,并强调未来在葡萄膜炎生物标志物开发、患者分层和精准医学方面的优先事项。
Uveitis, a leading cause of blindness, is driven by dysregulated immune responses, particularly autoreactive T cells. Despite advances in understanding its pathogenesis, key regulatory mechanisms remain elusive. Here, we integrate the cleavage under targets and tagmentation (CUT&Tag) and single-cell RNA sequencing (scRNA-seq) to delineate the super-enhancer (SE) landscape and transcriptional profiles of CD4+ T cells in Vogt-Koyanagi-Harada (VKH) disease. We identify serum/glucocorticoid-regulated kinase 1 (SGK1) as a key SE-associated gene, substantially up-regulated in CD4+ T cells of VKH patients. Pharmacological inhibition of SGK1 markedly alleviates uveitis in mice. Mechanistically, SE-driven SGK1 expression activates the MEK1-ERK1/2-ODC1 axis, leading to aberrant polyamine metabolism and a skewed T helper 17 (TH17)/regulatory T (Treg) balance, whereas polyamine supplementation negates these therapeutic benefits, confirming SGK1's role in driving disease progression. Notably, through molecular docking and molecular dynamics simulations, we identified herbacetin as a natural inhibitor of SGK1. Herbacetin restores immune balance and mitigates disease severity, highlighting SGK1 as a promising therapeutic target for autoimmune uveitis.
中文摘要:葡萄膜炎是导致失明的主要原因之一,其发生由免疫应答失调驱动,尤其是自身反应性T细胞。尽管对其发病机制的认识已有进展,但关键调控机制仍不清楚。本研究整合靶向切割与转座酶标记(CUT&Tag)和单细胞RNA测序(scRNA-seq),描绘了Vogt-Koyanagi-Harada(VKH)病患者CD4+ T细胞的超级增强子(SE)图谱和转录特征。我们鉴定出血清/糖皮质激素调节激酶1(SGK1)是一个关键的SE相关基因,其在VKH患者CD4+ T细胞中显著上调。药物抑制SGK1可明显减轻小鼠葡萄膜炎。机制上,SE驱动的SGK1表达激活MEK1-ERK1/2-ODC1轴,导致多胺代谢异常以及辅助性T细胞17(TH17)/调节性T细胞(Treg)平衡偏移,而补充多胺可抵消这些治疗获益,证实SGK1在推动疾病进展中的作用。值得注意的是,通过分子对接和分子动力学模拟,我们发现草质素是SGK1的天然抑制剂。草质素可恢复免疫平衡并减轻疾病严重程度,凸显SGK1作为自身免疫性葡萄膜炎有前景的治疗靶点。
2影像与人工智能 (2篇)
临床研究 (1篇)
Rosacea is a chronic central face dermatosis caused by a combination of dysregulated innate and adaptive immunity and hyperreactive cutaneous neurovasculature. Although classically associated with lighter skin phototypes, rosacea may affect up to 2-4% of Black, Asian, Pacific Islander, and Hispanic/Latino American populations and its prevalence is likely underestimated given our current diagnostic reliance on phenotypic expression (e.g., fixed erythema with or without intermittent exacerbations, flushing, and/or telangiectasias) that may be difficult to appreciate in more heavily pigmented skin. In patients with richly pigmented skin, a careful history of symptoms to assess the minor/secondary criteria (i.e., burning or stinging, edema, dryness, flushing, low tolerance for over-the-counter products, symptoms with classic 'triggers', family history and/or ocular symptoms), along with patient participation during the physical exam to establish their baseline skin tone, may facilitate diagnosis. Rosacea treatment regimens are centered around presentation and can include over-the-counter agents, lifestyle modifications, prescription topical, systemic, and procedural therapies. Optimal regimens may be tailored to best address patient-perceived disease severity and concerns and to minimize any further irritation/inflammation which may drive pigmentary alteration.
中文摘要:玫瑰痤疮是一种慢性面部中央区皮肤病,由固有免疫和适应性免疫失调以及皮肤神经血管高反应性共同引起。尽管传统上认为其与较浅肤色光型相关,但玫瑰痤疮可能影响高达2-4%的黑人、亚洲人、太平洋岛民和西班牙裔/拉丁裔美国人群体,而且由于我们目前的诊断依赖于表型表现(例如固定性红斑,伴或不伴间歇性加重、潮红和/或毛细血管扩张),这些表现在色素较深的皮肤中可能难以识别,因此其患病率很可能被低估。对于色素丰富的皮肤患者,仔细询问症状病史以评估次要/继发标准(即烧灼感或刺痛感、水肿、干燥、潮红、对非处方产品耐受性低、具有典型「诱因」的症状、家族史和/或眼部症状),并结合患者在体格检查中的参与以确定其基线肤色,可能有助于诊断。玫瑰痤疮治疗方案以临床表现为中心,可包括非处方药物、生活方式调整、处方外用、全身和程序化治疗。最佳方案可进行个体化调整,以最好地解决患者感知的疾病严重程度和关切,并尽量减少可能驱动色素改变的任何进一步刺激/炎症。
基础研究 (1篇)
Accurate assessment of ocular toxicity, drug safety, and therapeutic efficacy remains a significant challenge due to the complex anatomy and physiology of the human cornea. Furthermore, conventional two-dimensional (2D) cell cultures and animal models have key limitations. Recent advances in alternative corneal models-three-dimensional (3D) tissue-engineered constructs, organ-on-chip platforms, corneal organoids, and bio-printed systems have transformed ophthalmic research by offering improved physiological relevance and translational value. These advanced models better recapitulate the multilayered architecture, biomechanical properties, fluid dynamics, and cellular microenvironment of the native cornea, enabling more accurate investigation of drug penetration, toxicity, wound healing, and disease mechanisms. In alignment with current National Institutes of Health (NIH) initiatives promoting the replacement, reduction, and refinement of animal research and the promotion of New Approach Methodologies (NAMs), this review examines emerging corneal models that collectively represent a paradigm shift in ophthalmic research. We first outline conventional in vivo and in vitro corneal models to provide historical context and their limitations, followed by a discussion of next-generation technologies. These include cornea-on-chip systems that integrate microfluidics to represent tear flow, blinking, and biomechanical forces; corneal organoids derived from pluripotent stem cells that offer self-organizing, human-specific platforms for disease modeling and safety assessment; and advances in 3D bioprinting enabling the fabrication of mechanically adjustable corneal constructs. The review also highlights the importance of bioinformatics/artificial intelligence in predicting ocular responses and complementing experimental platforms. Collectively, we emphasize that these alternative, emerging technologies support ethical science, improve translational accuracy, and meet federal regulations while reducing animal testing.
中文摘要:由于人角膜复杂的解剖和生理结构,准确评估眼部毒性、药物安全性和治疗疗效仍然是一项重大挑战。此外,传统的二维(2D)细胞培养和动物模型存在关键局限性。替代角膜模型的最新进展——三维(3D)组织工程构建体、器官芯片平台、角膜类器官和生物打印系统——通过提供更好的生理相关性和转化价值,改变了眼科研究。这些先进模型能更好地再现天然角膜的多层结构、生物力学特性、流体动力学和细胞微环境,从而能够更准确地研究药物渗透、毒性、伤口愈合和疾病机制。为顺应当前美国国立卫生研究院(NIH)倡导的替代、减少和优化动物研究以及推广新方法学(NAMs)的举措,本综述探讨了新兴角膜模型,这些模型共同代表了眼科研究的范式转变。我们首先概述传统体内和体外角膜模型,以提供历史背景及其局限性,随后讨论下一代技术。这些技术包括整合微流控以模拟泪液流动、眨眼和生物力学力的角膜芯片系统;源自多能干细胞的角膜类器官,可提供自组织、人源特异性的平台用于疾病建模和安全性评估;以及3D生物打印的进展,使制造力学可调的角膜构建体成为可能。本综述还强调了生物信息学/人工智能在预测眼部反应和补充实验平台方面的重要性。总体而言,我们强调这些替代性新兴技术支持合乎伦理的科学,提高转化准确性,并满足联邦法规要求,同时减少动物测试。
3白内障与屈光手术 (1篇)
临床研究 (1篇)
Cataract is a highly prevalent cause of visual impairment and blindness worldwide. Although genome-wide association studies (GWAS) have mapped multiple cataract risk loci, further work is required towards translating these signals and integrating multi-omics evidence for preventing or delaying age-related cataract progression. A senile cataract GWAS was first conducted in All of Us, followed by ancestry-specific GWAS meta-analyses in European-ancestry (161,812 cases and 1,099,738 controls) and East Asian ancestry (66,679 cases and 521,995 controls). To prioritise candidate targets, we performed Mendelian randomisation (MR) and colocalisation using cis-expression quantitative trait loci (cis-eQTL) instruments from eQTLGen. We then conducted a plasma proteome-wide cis-pQTL MR scan with colocalisation using UKB-PPP and deCODE for European analyses, and cis-pQTL data from the China Kadoorie Biobank for East Asian analyses. We identified 78 and 4 independent loci for cataract in Europeans and East Asians, respectively, including 8 and 3 putatively unreported loci. By integrating the meta-GWAS with cis-eQTL MR, we prioritised 16 genes, including MTMR3, NT5DC2, and EFNA1, with eQTL-GWAS colocalisation further supporting MTMR3 and NT5DC2. Proteome-wide cis-pQTL MR prioritised 32 proteins for senile cataract in Europeans, and colocalisation refined these to EFNA1 and RALY. In East Asians, MR highlighted APOE and ALDH2 as candidate targets. We also identified colocalised pleiotropic signals shared between cataract and related traits, including myopia, hypertension, and type 2 diabetes, highlighting candidate genes such as TCF7L2, BMP4, CDKAL1, PAX4, and ALDH2. These findings advance cross-ancestry understanding of cataract genetic architecture and prioritise genetically supported candidates. This work was supported by the Joint Funds for the Innovation of Science and Technology, Fujian Joint Innovation Fund in Science and Technology Project (Grant No. 2025Y9437).
中文摘要:白内障是全球范围内导致视力损害和失明的高度常见原因。尽管全基因组关联研究(GWAS)已定位多个白内障风险位点,但仍需进一步工作来转化这些信号并整合多组学证据,以预防或延缓年龄相关性白内障进展。我们首先在All of Us中开展了老年性白内障GWAS,随后在欧洲血统(161,812例病例和1,099,738例对照)和东亚血统(66,679例病例和521,995例对照)中进行了血统特异性GWAS荟萃分析。为了对候选靶点进行优先排序,我们使用来自eQTLGen的顺式表达数量性状位点(cis-eQTL)工具变量进行了孟德尔随机化(MR)和共定位分析。随后,我们使用UKB-PPP和deCODE在欧洲分析中进行了血浆蛋白质组范围cis-pQTL MR扫描及共定位分析,并使用中国慢性病前瞻性研究(China Kadoorie Biobank)的cis-pQTL数据进行东亚分析。我们在欧洲人和东亚人中分别鉴定出78个和4个白内障独立位点,其中包括8个和3个推测未报道位点。通过将meta-GWAS与cis-eQTL MR整合,我们优先选出16个基因,包括MTMR3、NT5DC2和EFNA1,eQTL-GWAS共定位进一步支持MTMR3和NT5DC2。蛋白质组范围cis-pQTL MR在欧洲人中优先选出32个与老年性白内障相关的蛋白质,共定位将这些蛋白质进一步缩小至EFNA1和RALY。在东亚人中,MR突出显示APOE和ALDH2为候选靶点。我们还鉴定出白内障与相关性状(包括近视、高血压和2型糖尿病)之间共享的共定位多效性信号,突出显示了TCF7L2、BMP4、CDKAL1、PAX4和ALDH2等候选基因。这些发现推进了对白内障遗传结构的跨血统理解,并对有遗传学支持的候选靶点进行了优先排序。本研究得到福建省科技创新联合资金、福建省科技项目联合创新基金资助(项目编号:2025Y9437)。
4青光眼 (1篇)
临床研究 (1篇)
To evaluate the outcomes of a stepwise multimodal treatment approach for conjunctival melanocytic lesions ranging from low-grade conjunctival melanocytic intraepithelial lesion (LG-CMIL) through high-grade CMIL (HG-CMIL) to invasive conjunctival melanoma (iCoM) and to propose a practical management framework. Retrospective, single-centre cohort study. Patients diagnosed with LG-CMIL, HG-CMIL, or iCoM and managed at the Liverpool Ocular Oncology Centre between January 2015 and April 2025 were included. A sequential stepwise strategy was employed, comprising surgical excision or incisional biopsy, topical chemotherapy (mitomycin C, 5-fluorouracil, or interferon alpha-2b), and adjuvant Ruthenium-106 plaque brachytherapy or proton beam radiotherapy when indicated, selected according to histopathological grade and clinical growth pattern (focal versus diffuse). Kaplan-Meier survival analysis and Cox proportional hazards regression identified prognostic factors for recurrence and metastasis. Local recurrence was the primary endpoint; metastatic disease and residual pigmentation after primary therapy were the secondary endpoints. Among 165 eyes, including 39 LG-CMIL, 39 HG-CMIL, and 87 iCoM cases, HG-CMIL demonstrated the highest recurrence rate (24.3%; 9 eyes) and the earliest recurrence events (median 8.2 months), whereas LG-CMIL showed the lowest recurrence risk (11.1%; 4 eyes). Metastatic disease occurred exclusively in iCoM (11.4%; 8 eyes), accounting for 16.7% of deaths in the cohort. Non-bulbar involvement (HR 2.76, p=0.014) and residual pigmentation (HR 2.77, p=0.024) independently predicted local recurrence, while ulcerative features (HR 15.08, p=0.001), non-bulbar involvement (HR 7.28, p=0.015) and increased tumour thickness (HR 2.15, p=0.030) were associated with metastatic spread. A tailored sequential multimodal approach achieved satisfactory local disease control, with local recurrence being primarily driven by non-bulbar involvement and residual pigmentation after primary therapy, while metastatic spread was strongly associated with ulcerative features, followed by non-bulbar involvement and tumour thickness.
中文摘要:评估从低级别结膜黑素细胞上皮内病变(LG-CMIL)到高级别CMIL(HG-CMIL)再到浸润性结膜黑色素瘤(iCoM)的结膜黑素细胞病变采用阶梯式多模式治疗的结果,并提出实用管理框架。回顾性单中心队列研究。纳入2015年1月至2025年4月在利物浦眼科肿瘤中心诊治的LG-CMIL、HG-CMIL或iCoM患者。采用序贯阶梯策略,包括手术切除或切开活检、局部化疗(丝裂霉素C、5-氟尿嘧啶或干扰素α-2b),以及在有指征时辅助钌-106敷贴器近距离放疗或质子束放疗,并根据组织病理学分级和临床生长模式(局灶性与弥漫性)进行选择。采用Kaplan-Meier生存分析和Cox比例风险回归确定复发和转移的预后因素。局部复发为主要终点;转移性疾病和初始治疗后残留色素为次要终点。在165只眼中,包括39例LG-CMIL、39例HG-CMIL和87例iCoM,HG-CMIL复发率最高(24.3%;9眼),复发事件最早(中位8.2个月),而LG-CMIL复发风险最低(11.1%;4眼)。转移仅发生于iCoM(11.4%;8眼),占该队列死亡的16.7%。非球部受累(HR 2.76,p=0.014)和残留色素(HR 2.77,p=0.024)独立预测局部复发,而溃疡特征(HR 15.08,p=0.001)、非球部受累(HR 7.28,p=0.015)和肿瘤厚度增加(HR 2.15,p=0.030)与转移扩散相关。个体化序贯多模式治疗实现了满意的局部疾病控制,局部复发主要由非球部受累和初始治疗后残留色素驱动,而转移扩散与溃疡特征密切相关,其次为非球部受累和肿瘤厚度。
5视网膜疾病 (1篇)
基础研究 (1篇)
The Virtual Eye initiative described here seeks to build a versatile and integrative in silico platform, 'The Virtual Eye' that can capture and simulate the biology, physiology and function of the human eye, from molecular interactions to organ-level behaviour, in both healthy and diseased states. This effort has the potential to substantially deepen our understanding of the visual process, clarify the mechanistic basis of ocular diseases across multiple spatial and temporal scales, and support the development of therapeutic strategies for both common and rare eye conditions. A coordinated undertaking among biologists, biophysicists, clinicians, mathematicians and engineers has led to the development of a shared roadmap and collaborative investigations into foundational challenges, including for instance retinal vascular flow and the progression of geographic atrophy lesions in age-related macular degeneration (AMD). Here, we present an initial framework for advancing the Virtual Eye and define core models required to ensure its coherent development and expansion. This framework is rooted in current knowledge of biological mechanisms and integrated with mathematical representation, with the initial ambition of simulating a defined period of healthy function using a range of stimuli and experiments representing the natural world. We identify nine core modelling tasks that capture the healthy physiology of the eye and outline seven disease processes representing perturbations of normal function. Together, these components could form the first iteration of the Virtual Eye conceptual framework and roadmap for building it, enabling controlled experimental manipulation of a simulated system designed to generate realistic and biologically meaningful behaviours.
中文摘要:此处描述的「虚拟眼」计划旨在构建一个通用且整合的计算机模拟平台——「虚拟眼」,该平台能够捕捉并模拟人类眼在健康与疾病状态下的生物学、生理学与功能,从分子相互作用到器官水平行为。这项工作有望大幅加深我们对视觉过程的理解,阐明跨多个空间与时间尺度的眼部疾病机制基础,并支持常见与罕见眼病治疗策略的开发。生物学家、生物物理学家、临床医生、数学家和工程师之间的协同努力促成了一份共享路线图的制定,并围绕基础性挑战开展合作研究,例如视网膜血管血流以及年龄相关性黄斑变性(AMD)中地图样萎缩病灶的进展。在此,我们提出推进「虚拟眼」的初步框架,并定义确保其连贯发展与扩展所需的核心模型。该框架植根于当前对生物学机制的认识,并与数学表达相结合,其初步目标是利用一系列代表自然世界的刺激与实验来模拟特定时长的健康功能。我们确定了九项核心建模任务,用以捕捉眼的健康生理学,并概述了七种代表正常功能扰动的疾病过程。这些组成部分共同构成了「虚拟眼」概念框架及其构建路线图的第一版,使得能够对旨在产生真实且具有生物学意义行为的模拟系统进行受控实验操作。
6眼肿瘤 (1篇)
临床研究 (1篇)
Retinoblastoma (RB) outcomes in low- and middle-income countries remain inferior to those achieved in high-income countries, largely due to delayed diagnosis, limited access to specialized care, and fragmented treatment systems. The aim of this study is to evaluate the long-term impact of a two-decade strategy based on centralized multidisciplinary care, structured capacity building, and a telemedicine-supported international twinning partnership in reducing disparities in retinoblastoma (RB) outcomes in a resource-limited setting. Retrospective, single-center cohort study. 601 children with RB (1000 affected eyes) treated at King Hussein Cancer Center (KHCC) between March 2003 and December 2025. Demographic characteristics, tumor classification, treatment modalities, globe salvage, metastasis, secondary malignancies, and survival outcomes were reviewed. Overall survival was estimated using the Kaplan-Meier method. Globe salvage rate, rates of metastasis and secondary malignancy, and 5-year overall survival. Of 601 children, 314 (52%) were male, 399 (66%) had bilateral disease, and 346 (58%) were non-Jordanian, referred from 15 countries. Of 1000 affected eyes, 120 (12%) were enucleated before referral; among the remaining eyes, 7 (0.7%) had extraocular disease, and by International Classification, 52 (5.2%) were Group A, 134 (13%) Group B, 204 (20%) Group C, 391 (39%) Group D, and 92 (9.2%) Group E. Of 880 eyes treated at KHCC, primary enucleation was performed in 157 (18%), and conservative eye-salvage therapy was attempted in 723 (82%). Among the 723 eyes that underwent eye-salvaging treatment, systemic chemotherapy was administered in 713 (99%), transpupillary thermo therapy (TTT) in all 723 (100%), cryotherapy in 248 (34%), intra-arterial chemotherapy in 34 (4.7%; 11 primary and 23 secondary), intravitreal chemotherapy in 43 (5.9%), subtenon chemotherapy in 24 (3.3%), and iodine-125 plaque brachytherapy in 23 (3.2%). Ten Group A eyes in 10 patients were treated with TTT and/or cryotherapy alone without systemic chemotherapy. Overall eye salvage rate was 61% (538/880); among conservatively treated eyes, salvage rate was 74.4% (538/723), ranging from 98% (Group A) to 17% (Group E). At median follow-up of 120 months, metastasis occurred in 26 patients (4.3%) and secondary malignancy in 7 (1.2%). Estimated 5-year overall survival was 96% (95% CI, 94%-98%). A centralized multidisciplinary RB program integrating telemedicine, international collaboration, and advanced globe-salvage therapies achieved survival and eye-preservation outcomes comparable to high-income settings despite resource constraints. Over two decades, KHCC evolved into a major regional referral center, offering a scalable model for reducing global disparities in RB care. None.
中文摘要:在低收入和中等收入国家,视网膜母细胞瘤(RB)的结局仍差于高收入国家,主要原因包括诊断延迟、获得专科治疗的机会有限以及治疗体系碎片化。本研究旨在评估一项为期二十年、以集中式多学科诊疗、结构化能力建设和远程医疗支持的国际结对合作为基础的战略,在资源有限环境中缩小视网膜母细胞瘤(RB)结局差异方面的长期影响。回顾性单中心队列研究。研究纳入2003年3月至2025年12月在侯赛因国王癌症中心(KHCC)接受治疗的601例RB患儿(1000只受累眼)。回顾人口学特征、肿瘤分类、治疗方式、保眼、转移、第二恶性肿瘤和生存结局。采用Kaplan-Meier法估计总生存。主要观察指标为保眼率、转移率和第二恶性肿瘤发生率以及5年总生存率。601例患儿中,314例(52%)为男性,399例(66%)为双侧病变,346例(58%)为非约旦籍,来自15个国家转诊。1000只受累眼中,120只(12%)在转诊前已行眼球摘除;在其余眼中,7只(0.7%)存在眼外疾病,按国际分类,A组52只(5.2%),B组134只(13%),C组204只(20%),D组391只(39%),E组92只(9.2%)。在KHCC接受治疗的880只眼中,157只(18%)行初次眼球摘除,723只(82%)尝试保守保眼治疗。在接受保眼治疗的723只眼中,全身化疗用于713只(99%),经瞳孔温热疗法(TTT)用于全部723只(100%),冷冻治疗用于248只(34%),动脉内化疗用于34只(4.7%;11只为初次,23只为再次),玻璃体腔化疗用于43只(5.9%),眼球筋膜下化疗用于24只(3.3%),碘-125敷贴器近距离放疗用于23只(3.2%)。10例患者的10只A组眼仅接受TTT和/或冷冻治疗,未接受全身化疗。总体保眼率为61%(538/880);在接受保守治疗的眼中,保眼率为74.4%(538/723),范围从A组的98%到E组的17%。中位随访120个月时,26例患者(4.3%)发生转移,7例(1.2%)发生第二恶性肿瘤。估计5年总生存率为96%(95%CI,94%-98%)。一个整合远程医疗、国际合作和先进保眼治疗的集中式多学科RB项目,尽管资源受限,仍取得了与高收入地区相当的生存和保眼结局。二十年来,KHCC已发展为重要的区域转诊中心,为缩小全球RB诊疗差距提供了一种可推广的模式。无。